title: Therapeutic implications of orally delivered immunomodulatory oligonucleotides.
authors: Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
authors: Dennis M
authors: DM
authors: Klinman
mesh_terms: D000818:Animals; D003876:Dermatitis, Atopic / Q000276:immunology*; D016503:Drug Delivery Systems; D008297:Male; D053769:Nanocapsules; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D053769:Nanocapsules; D009838:Oligodeoxyribonucleotides
references: J Immunol. 2003 Aug 1;171(3):1393-400
references: 12874230
references: Mol Ther. 2015 Feb;23(2):297-309
references: 25502904
references: Nat Rev Drug Discov. 2006 Jun;5(6):471-84
references: 16763660
references: Antisense Nucleic Acid Drug Dev. 2001 Aug;11(4):247-56
references: 11572601
references: Ann N Y Acad Sci. 2009 Sep;1175:80-8
references: 19796080
references: Immunology. 2014 May;142(1):24-31
references: 24329495
references: Nat Rev Immunol. 2004 Apr;4(4):249-58
references: 15057783
references: Vaccine. 2014 Nov 12;32(48):6377-89
references: 24975812
references: FEBS Open Bio. 2012 Nov 12;3:41-5
references: 23847756
references: Vaccine. 2000 Oct 15;19(4-5):413-22
references: 11027803
references: Virulence. 2013 Apr 1;4(3):207-12
references: 23334153
references: J Immunol. 2005 Apr 15;174(8):4579-83
references: 15814679
references: J Immunol. 2012 Feb 15;188(4):1592-9
references: 22231700
references: EMBO J. 1994 Feb 15;13(4):993-1001
references: 8112312